Orion Portfolio Solutions LLC Has $1.78 Million Stock Position in Exelixis, Inc. (NASDAQ:EXEL)

Orion Portfolio Solutions LLC reduced its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 9.7% in the 4th quarter, Holdings Channel.com reports. The firm owned 53,528 shares of the biotechnology company’s stock after selling 5,729 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Exelixis were worth $1,782,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of EXEL. Vanguard Group Inc. raised its position in shares of Exelixis by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 29,429,252 shares of the biotechnology company’s stock valued at $979,994,000 after buying an additional 121,750 shares during the last quarter. Norges Bank acquired a new position in Exelixis in the 4th quarter valued at approximately $94,867,000. FMR LLC lifted its position in shares of Exelixis by 6.1% in the 3rd quarter. FMR LLC now owns 2,462,072 shares of the biotechnology company’s stock worth $63,891,000 after acquiring an additional 140,568 shares during the period. Los Angeles Capital Management LLC grew its holdings in shares of Exelixis by 20.4% during the 4th quarter. Los Angeles Capital Management LLC now owns 2,156,996 shares of the biotechnology company’s stock worth $71,828,000 after purchasing an additional 366,141 shares in the last quarter. Finally, Two Sigma Advisers LP increased its position in shares of Exelixis by 6.1% during the third quarter. Two Sigma Advisers LP now owns 1,702,590 shares of the biotechnology company’s stock valued at $44,182,000 after purchasing an additional 98,000 shares during the period. 85.27% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Exelixis news, Director Jack L. Wyszomierski sold 8,768 shares of Exelixis stock in a transaction on Friday, February 28th. The shares were sold at an average price of $37.80, for a total value of $331,430.40. Following the sale, the director now directly owns 356,605 shares in the company, valued at approximately $13,479,669. The trade was a 2.40 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Patrick J. Haley sold 10,000 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $38.80, for a total transaction of $388,000.00. Following the sale, the executive vice president now directly owns 341,028 shares in the company, valued at $13,231,886.40. This trade represents a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 140,343 shares of company stock valued at $5,177,234. 2.85% of the stock is owned by corporate insiders.

Exelixis Stock Performance

EXEL opened at $37.04 on Thursday. Exelixis, Inc. has a twelve month low of $20.14 and a twelve month high of $40.02. The firm has a market cap of $10.37 billion, a PE ratio of 20.93, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57. The firm’s fifty day moving average is $35.80 and its two-hundred day moving average is $33.48.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. Equities analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on EXEL. Guggenheim reiterated a “buy” rating and set a $42.00 price target on shares of Exelixis in a research note on Wednesday, February 12th. Barclays upped their target price on shares of Exelixis from $25.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, February 13th. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Exelixis in a research note on Thursday, March 27th. Truist Financial lifted their price objective on Exelixis from $42.00 to $43.00 and gave the company a “buy” rating in a report on Monday, January 27th. Finally, Morgan Stanley raised Exelixis from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $30.00 to $40.00 in a report on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $37.59.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.